Table 4.
First-line treatment
| Treatment | Category | Colorectal cancer | Breast cancer | Prostate cancer |
| None (active surveillance) | – | – | 38 (3.6%) | |
| Surgery | Total: 1999 (95.3%) | Conservative: 1231 (73.1%) |
Prostatectomy: 639 (61.4%) | |
| Resection: 1800 (85.8%) | ||||
| Palliative: 127 (6.1%) | Mastectomy: 454 (26.9%) |
|||
| No resection: 61 (2.9%) | ||||
| Others: 11 (0.5%) | ||||
| Chemotherapy | Neoadjuvant | 427 (20.4%) | 200 (11.9%) | 1 (0.1%) |
| Adjuvant | 1024 (48.8%) | 664 (39.4%) | 1 (0.1%) | |
| Palliative | 67 (3.2%) | 25 (1.5%) | 7 (0.7%) | |
| Radiotherapy | Neoadjuvant | 401 (19.1%) | 5 (0.3%) | 227 (21.5%) |
| Adjuvant | 82 (3.9%) | 1132 (67.2%) | 36 (3.4%) | |
| Palliative | 5 (0.2%) | 21 (1.2%) | 2 (0.2%) | |
| Endocrine therapy | Yes | – | 1023 (60.7%) | Adjuvant to surgery: 19 (1.8%) |
| Adjuvant to radiotherapy: 99 (9.4%) | ||||
| Neoadjuvant: 102 (9.7%) | ||||
| Palliative: 69 (6.5%) | ||||
| No | – | 662 (39.3%) | 689 (65.3%) | |
| Others (specify for each tumour) | Endoscopy | Complete resection: 107 (5.1%) | – | – |
| Non-complete resection: 62 (3.0%) | ||||
| Her2-targeted therapy | – | 152 (9.0%) | – | |
| Cryotherapy | – | – | 21 (2.0%) | |
| Transurethral resection | – | – | 4 (0.4%) |